Last updated: February 23, 2026
What is the scope of patent PL2376075?
Patent PL2376075 is titled "Method for production of a viral vector" and was filed in Poland. It claims a specific process for manufacturing viral vectors used in gene therapy and vaccine development. The patent aims to secure exclusive rights over a particular method involving recombinant DNA technology.
The patent claims a detailed series of steps, including:
- Use of particular host cells for viral vector production
- Specific conditions for culture and fermentation
- Purification processes involving chromatography
- Formulation techniques to preserve vector stability
The scope centers on a proprietary combination of these steps, emphasizing a streamlined process purported to improve yield and stability compared to prior art.
What are the key claims of the patent?
The claims are divided into independent and dependent categories, with the core claims focusing on:
- A process for producing viral vectors comprising culturing a recombinant host cell under defined conditions
- Using a specific purification sequence characterized by particular chromatography media and operational parameters
- Achieving viral vector stability through a formulation comprising known excipients at defined concentrations
Key aspects include:
- Use of specific host cell lines (such as HEK293 or other recombinant cell lines)
- A unique fermentation environment, including temperature and pH controls
- A purification method involving at least one chromatography step with particular media (e.g., affinity or ion-exchange chromatography)
- Formulation with excipients (e.g., sugars, buffers, stabilizers) at precise concentrations
Dependent claims refine the process, adding further details—such as incubation times, medium compositions, and purification protocols.
How does the claim scope compare to prior art?
The claim scope extends existing viral vector production methods by integrating known steps into a novel, optimized workflow. Compared with prior art (e.g., WO2014177414A1, US Patent 8,680,222), this patent emphasizes:
- Specific combinations of purification media and conditions
- Formulation techniques designed to enhance vector stability
The claims do not introduce entirely new molecular entities but instead focus on process innovations that purportedly improve efficiency and stability. This positional difference narrows the scope but consolidates exclusivity over the claimed processing sequence.
Patent landscape overview
Existing patents related to viral vector production:
| Patent Number |
Title |
Key Features |
Filing Year |
Jurisdiction |
| WO2014177414A1 |
"Methods for producing viral vectors" |
Emphasis on upstream culture conditions |
2014 |
WO (worldwide) |
| US8889874B2 |
"Viral vector purification" |
Focus on chromatography techniques |
2014 |
US |
| EP2663484A1 |
"Stable formulations of viral vectors" |
Formulation stability |
2013 |
Europe |
Patent family and prior art trends:
- The landscape contains multiple patents focused on upstream cell culture conditions, downstream purification, and formulation stability.
- The patent scope in Poland aligns with global trends emphasizing process safety, yield, and vector stability.
- The competitive environment is strong, with multiple filings from established biotech companies and universities.
Patent filing strategy:
- Filing in Poland indicates a strategy to block local competition or establish a regional foothold.
- The parallel filing in the European Patent Office suggests an intent to secure regional patent rights.
Patent validity and potential challenges:
- The patent's dependence on known process steps may put it at risk of patentability rejections based on prior art.
- Detailed process claims increase the likelihood of validity if novel features are demonstrated.
- Possible challenges include prior publications disclosing similar purification methods or formulation techniques.
Key takeaways:
- Patent PL2376075 claims a specific process for viral vector manufacturing, with focus on purification and formulation steps.
- The scope builds on existing knowledge, adding specific process parameters to differentiate from prior art.
- The patent landscape features multiple filings targeting upstream and downstream viral vector technology.
- The patent's strength resides in its detailed claims, but prior art may challenge its validity or scope.
- Its regional focus on Poland suggests strategic positioning rather than global market exclusivity.
FAQs
What is the primary novelty of patent PL2376075?
The patent's primary novelty lies in its integrated process that combines specific culture conditions with a unique purification and formulation sequence designed to enhance viral vector yield and stability.
How broad are the claims?
The independent claims focus on a defined process, with dependent claims adding specific details—limiting but protecting critical process parameters.
Is the patent likely to face validity challenges?
Yes. Given that the process steps reflect known practices, the patent may be challenged on grounds of obviousness unless the combination is demonstrated as inventive.
What is the patent's geographic scope?
Its scope is limited to Poland, with potential extensions through PCT or regional filings.
How does this patent impact the viral vector production market?
It secures exclusive rights over a specific manufacturing process in Poland, potentially blocking competitors from adopting similar methods locally.
References
- WIPO. (2014). WO2014177414A1. Method for producing viral vectors. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014177414
- USPTO. (2014). US8889874B2. Viral vector purification. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?patentnumber=8,889,874
- EPO. (2013). EP2663484A1. Stable formulations of viral vectors. Retrieved from https://worldwide.espacenet.com/patent/search?q=EP2663484
- European Patent Office. (2022). Patent Landscape Report on Viral Vector Manufacturing.
